Optimization of single injection liver arterial phase gadolinium enhanced MRI using bolus track real-time imaging.

PURPOSE: To measure contrast agent enhancement kinetics in the liver and to further evaluate and develop an optimized gadolinium enhanced MRI using a single injection real-time bolus-tracking method for reproducible imaging of the transient arterial-phase. MATERIALS AND METHODS: A total of 18 subjects with hypervascular liver lesions were imaged with four dimensional (4D) perfusion scans to measure time-to-peak (TTP) delays of arterial (aorta-celiac axis), liver parenchyma, liver lesion, portal, and hepatic veins. Time delays were calculated from the TTP-aorta signal, and then related to the gradient echo (GRE) k-space acquisition design, to determine optimized timing for real-time bolus-track triggering methodology. As another measure of significance, 200 clinical patients were imaged with 3D-GRE using either a fixed time-interval or by individualized arterial bolus real-time triggering. Bolus TTP-aorta was calculated and arterial-phase acquisitions were compared for accuracy and reproducibility using specific vascular enhancement indicators. RESULTS: The mean bolus transit-time to peak-lesion contrast was 8.1 ± 2.7 seconds following arterial detection, compared to 32.1 ± 5.4 seconds from contrast injection, representing a 62.1% reduction in the time-variability among subjects (N = 18). The real-time bolus-triggered technique more consistently captured the targeted arterial phase (94%), compared to the fixed timing technique (73%), representing an expected improvement of timing accuracy in 28% of patients (P = 0.0001389). CONCLUSION: Our results show detailed timing window analysis required for optimized arterial real-time bolus-triggering acquisition of transient arterial phase features of liver lesions, with optimized arterial triggering expected to improve reproducibility in a significant number of patients.

Individual kidney blood flow measured with contrast-enhanced first-pass perfusion MR imaging.

UNLABELLED: The study design was HIPAA-compliant and approved by the Institutional Review Board, with all participants providing signed informed consent prior to the study. The purpose of this study was to prospectively evaluate the feasibility of determining renal blood flow (RBF) by using a technique based on intravenous administration of gadolinium chelate and evaluation of first-pass gadolinium chelate perfusion by using highly accelerated three-dimensional (3D) gradient-echo magnetic resonance (MR) imaging of the kidney in freely breathing subjects. Flow is determined with Kety-Schmidt formalism by modeling the uptake of gadolinium chelate in the kidney prior to its leaving through the venous system. Validation of the gadolinium chelate perfusion technique is based on comparison of values determined for participants with phase-contrast gradient-echo imaging. The model fit to the measured data is excellent over the first 7-8 seconds of gadolinium chelate uptake and diverges after its appearance in the renal vein. The perfusion data analysis technique showed less than 10% interobserver variation. The average difference between phase-contrast and gadolinium chelate perfusion measurements was 0.08 mL/sec (95% confidence interval: -3.73, 3.58) for left and right kidneys. This study demonstrates feasibility of the gadolinium chelate perfusion method for RBF measurement and discusses potential applications. SUPPLEMENTAL MATERIAL: http://radiology.rsnajnls.org/cgi/content/full/246/1/241/DC1.